Efficacy by baseline disease characteristics of subcutaneous guselkumab induction therapy in patients with moderately to severely active Crohn's disease: Results at Week 12 from the phase 3 GRAVITI study

Category Primary study
JournalJ. Crohn's Colitis
Year 2025
This article has no abstract
Epistemonikos ID: c10336142a19913795bb1360b655fbdbd4699212
First added on: Feb 26, 2025